Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2B6 | P20813 | 1/20 | 1.00 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 11/20 | 0.46 |
| ▸ | TBXAS1 | P24557 | 4/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | QPCT | Q16769 | 1/20 | 0.42 |
| ▸ | OGG1 | O15527 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11047040 | 1.00 | CYP2B6 (1.00) | CYP2B6HRH4HRH3CYP19A1TBXAS1 | |
| SCHEMBL11046868 | 1.00 | CYP2B6 (1.00) | CYP2B6HRH4HRH3CYP19A1TBXAS1 | |
| SCHEMBL20076324 | 1.00 | CYP2B6 (1.00) | CYP2B6HRH4HRH3CYP19A1TBXAS1 | |
| SCHEMBL11046639 | 1.00 | CYP2B6 (1.00) | CYP2B6HRH4HRH3CYP19A1TBXAS1 | |
| Water SCHEMBL29258020 | 0.98 | CYP2B6 (0.96) | CYP2B6HRH4HRH3CYP19A1TBXAS1 | |
| Hydrochloric Acid SCHEMBL11047046 | 0.98 | CYP2B6 (0.96) | CYP2B6HRH4HRH3CYP19A1TBXAS1 | |
| Iodide SCHEMBL16164466 | 0.98 | CYP2B6 (0.96) | CYP2B6HRH4HRH3CYP19A1TBXAS1 | |
| SCHEMBL11047050 | 0.98 | CYP2B6 (0.96) | CYP2B6HRH4HRH3CYP19A1TBXAS1 | |
| SCHEMBL11051252 | 0.94 | CYP2B6 (0.89) | CYP2B6CYP19A1TBXAS1 | |
| Oxalic Acid SCHEMBL11048695 | 0.90 | CYP2B6 (0.81) | CYP2B6CYP19A1TBXAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120196905-A1 | SYNTHETIC COMPOUNDS AND METHODS TO DECREASE NICOTINE SELF-ADMINISTRATION | HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) | 2012-08-02 | — | — | US | claimed |
| WO-2012019093-A1 | SYNTHETIC COMPOUNDS AND METHODS TO DECREASE NICOTINE SELF-ADMINISTRATION | HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) | 2012-02-09 | — | — | WO | claimed |
| EP-0000951-B1 | PHARMACEUTICAL FORMULATIONS COMPRISING 1-SUBSTITUTED IMIDAZOLES, 1-SUBSTITUTED IMIDAZOLES AND 1-SUBSTITUTED IMIDAZOLES FOR USE IN THE TREATMENT OR PROPHYLAXIS OF THROMBO-EMBOLIC DISORDERS | THE WELLCOME FOUNDATION LIMITED (GB) | 1984-05-23 | — | — | EP | claimed |
| US-4284641-A | ANTITHROMBOEMBOLIC AGENT | BURROUGHS WELLCOME CO. (US) | 1981-08-18 | — | — | US | claimed |
| EP-0000951-A1 | Pharmaceutical Formulations comprising 1-substituted imidazoles, 1-substituted imidazoles and 1-substituted imidazoles for use in the treatment or prophylaxis of thrombo-embolic disorders | THE WELLCOME FOUNDATION LIMITED (GB) | 1979-03-07 | — | — | EP | claimed |
| EP-3307739-A1 | NRF2 REGULATORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2018-04-18 | — | — | EP | disclosed |
| US-9598342-B2 | Production of acetic acid with enhanced catalyst stability | CELANESE INTERNATIONAL CORPORATION (US) | 2017-03-21 | — | — | US | disclosed |
| WO-2016202253-A1 | NRF2 REGULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2016-12-22 | — | — | WO | disclosed |
| CN-102387992-B | Molecular sieve and correlation technique and structure directing agent | 加利福尼亚技术学院 | 2016-07-06 | — | — | CN | disclosed |
| US-8906943-B2 | Synthetic compounds and methods to decrease nicotine self-administration | HUMAN BIOMOLECULAR RESEARCH INSTITUTE | 2014-12-09 | — | — | US | disclosed |
| US-8906943-B2 | Synthetic compounds and methods to decrease nicotine self-administration | HUMAN BIOMOLECULAR RESEARCH INSTITUTE | 2014-12-09 | — | — | US | disclosed |
| US-8906943-B2 | Synthetic compounds and methods to decrease nicotine self-administration | HUMAN BIOMOLECULAR RESEARCH INSTITUTE | 2014-12-09 | — | — | US | disclosed |
| US-4591594-A | INSULIN LOWERING AGENTS | HOFFMANN-LA ROCHE INC. (US) | 1986-05-27 | — | — | US | disclosed |
| US-4581370-A | Antiarrhythmic imidazoliums | SCHERING A.G. (DE) | 1986-04-08 | — | — | US | disclosed |
| US-4500540-A | DIETETICS | HOFFMANN-LA ROCHE INC. (US) | 1985-02-19 | — | — | US | disclosed |
| EP-0131302-A2 | Imidazolium salts, intermediates thereto and their use | SCHERING AKTIENGESELLSCHAFT (DE) | 1985-01-16 | — | — | EP | disclosed |
| EP-0000951-B1 | PHARMACEUTICAL FORMULATIONS COMPRISING 1-SUBSTITUTED IMIDAZOLES, 1-SUBSTITUTED IMIDAZOLES AND 1-SUBSTITUTED IMIDAZOLES FOR USE IN THE TREATMENT OR PROPHYLAXIS OF THROMBO-EMBOLIC DISORDERS | THE WELLCOME FOUNDATION LIMITED (GB) | 1984-05-23 | — | — | EP | disclosed |
| EP-0000950-B1 | IMIDAZOLE DERIVATIVES AND SALTS THEREOF AND THEIR SYNTHESIS | THE WELLCOME FOUNDATION LIMITED (GB) | 1984-02-01 | — | — | EP | disclosed |
| US-4284641-A | ANTITHROMBOEMBOLIC AGENT | BURROUGHS WELLCOME CO. (US) | 1981-08-18 | — | — | US | disclosed |
| EP-0000951-A1 | Pharmaceutical Formulations comprising 1-substituted imidazoles, 1-substituted imidazoles and 1-substituted imidazoles for use in the treatment or prophylaxis of thrombo-embolic disorders | THE WELLCOME FOUNDATION LIMITED (GB) | 1979-03-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120196905-A1 | SYNTHETIC COMPOUNDS AND METHODS TO DECREASE NICOTINE SELF-ADMINISTRATION | SLC6A3, NNT, SLC6A2 | CYP2B6 902/4885HRH4 751/4885HRH3 998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.